Business
Admission to AIM
Admission to AIM.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 6276C Cambridge Cognition Holdings PLC 18 April 2013 \n \n\n\nCambridge Cognition Holdings Plc \n(\"Cambridge Cognition\" or the \"Company\")\n \nFirst Day of Dealings and Admission to Trading on AIM\nPlacing to Raise £6.4m\n \nCambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces the commencement, at 08.00 UK time this morning, of dealings in its Ordinary Shares on AIM, a market operated by the London Stock Exchange plc.\n \nHighlights \n• On Admission, Cambridge Cognition has raised approximately £5.0m (before expenses) in the Placing of New Ordinary Shares and certain existing Shareholders have realised a further £1.4m through the Sale of existing Ordinary Shares\n• Placing Price for Placing Shares and Sale Shares was 70 pence per Ordinary Share\n• Market capitalisation of the Company following the Placing and at Admission is approximately £11.8m\n• Total number of Ordinary Shares in issue at Admission is 16,885,105\n• finnCap Limited acted as Nominated Adviser and Broker to the Company\n• Baker Botts (UK) LLP provided legal advice in respect to the Company's admission to AIM\n• Cambridge Cognition's trading symbol is COG and the Company's ISIN code is GB00B8DV9647\n \nAbout Cambridge Cognition\nCambridge Cognition develops and commercialises computerised neuropsychological tests for sale worldwide, principally in the UK, the US and Europe. Cambridge Cognition has created two well-established products, CANTABelect™ and CANTABeclipse™, which as standalone reportable segments have been profitable in each of the last three years. CANTABelect™ is for use in regulated clinical trials and CANTABeclipse™ is designed for use by...